Literature DB >> 19626817

Type 2 diabetes, impaired fasting glucose, and their association with increased hepatic enzyme levels among the employees in a university hospital in Thailand.

Wiroj Jiamjarasrangsi1, Somrat Lertmaharit, Somkiat Sangwatanaroj, Vitool Lohsoonthorn.   

Abstract

The purpose of the present study was to examine the association between abnormal hepatocellular functions and abnormal fasting glucose level in the employees in a university hospital in Bangkok, Thailand. A cross-sectional data analysis was conducted among 2790 workers who were 35-60 years old and participated in both the annual fasting plasma glucose (FPG) examination and the baseline questionnaire survey during 2001-2005. The prevalence rates (95% confidence interval; CI) of impaired fasting glucose (IFG) were 10.4 (9.1-11.7) and 20.3 (17.0-23.9) percent respectively for women and men, while those of type 2 diabetes were 3.1 ( 2.4-3.9) and 6.5 (4.6-8.9) respectively. After controlling for conventional risk factors, only the alanine aminotransferase (ALT) level was significantly associated with increased abnormal FPG This association was particularly obvious for the DM. In conclusion, the present study demonstrated that the type 2 diabetes and ALT association was also evident in the Thai population.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19626817

Source DB:  PubMed          Journal:  J Med Assoc Thai        ISSN: 0125-2208


  3 in total

1.  Statistical properties on semiparametric regression for evaluating pathway effects.

Authors:  Inyoung Kim; Herbert Pang; Hongyu Zhao
Journal:  J Stat Plan Inference       Date:  2013-04       Impact factor: 1.111

2.  Bayesian semiparametric regression models for evaluating pathway effects on continuous and binary clinical outcomes.

Authors:  Inyoung Kim; Herbert Pang; Hongyu Zhao
Journal:  Stat Med       Date:  2012-03-22       Impact factor: 2.373

Review 3.  PNPLA3 rs738409 underlies treatment response in nonalcoholic fatty liver disease.

Authors:  Jin-Zhi Wang; Hai-Xia Cao; Jian-Neng Chen; Qin Pan
Journal:  World J Clin Cases       Date:  2018-08-16       Impact factor: 1.337

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.